The F.D.A. made the product review a priority, citing shortages that occurred in the wake of several recalls of drugs that were found to contain potentially cancer-causing chemicals. Health The New York TimesBy DENISE GRADY from NYT Health https://ift.tt/2XRWcE2
March 11, 2019 at 02:00PM
No comments:
Post a Comment